“Although immune checkpoint inhibition is used to treat many cancers, for most cancer types fewer than 50% of patients respond to therapy. Therefore, identifying biomarkers of immune checkpoint inhibition response could allow greater precision in therapy selection,” Vivek Naranbhai, PhD, MB, ChB, clinical fellow in medicine at Dana-Farber Cancer Institute, told Healio. Read more . . .
A form of the HLA-A gene appeared associated with shorter survival among patients treated with immune checkpoint inhibitors, according to a study published in The Lancet Oncology.The gene, HLA-A*03, is found in 2% to 16% of the U.S. population, researchers noted.